E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators
about
Observational versus experimental studies: what's the evidence for a hierarchy?Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weighRandomized, controlled trials, observational studies, and the hierarchy of research designsCurrent Controlled Trials: an opportunity to help improve the quality of clinical researchImmunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridgeTowards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnectShiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4New insights into acute lung injury.Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.Efficacy of a novel endotoxin adsorber polyvinylidene fluoride fiber immobilized with (L)-serine ligand on septic pigs.Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity.A novel role of kukoamine B: Inhibition of the inflammatory response in the livers of lipopolysaccharide-induced septic mice via its unique property of combining with lipopolysaccharide.Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.Harvesting, identification and barrier function of human lung microvascular endothelial cellsInterleukin 5 is protective during sepsis in an eosinophil-independent manner.Endotoxin Elimination in Patients with Septic Shock: An Observation Study.Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.Pediatric Sepsis - Part I: "Children are not small adults!"Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.New strategy for sepsis: Targeting a key role of platelet-neutrophil interaction.Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.Lymphocytes, apoptosis and sepsis: making the jump from mice to humans.Protective Effects of Huang-Lian-Jie-Du-Tang against Polymicrobial Sepsis Induced by Cecal Ligation and Puncture in Rats.Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial.Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis.Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.The immune response: targets for the treatment of severe sepsis.Cytokines in the systemic inflammatory response syndrome: a reviewThe EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.Insights and limits of translational research in critical care medicine.Microbial recognition and danger signals in sepsis and trauma.Low-dose polymyxin: an option for therapy of Gram-negative sepsis.Clavanin A improves outcome of complications from different bacterial infectionsA targeted extracorporeal therapy for endotoxemia: the time has come.Serious adverse events in academic critical care research.Precision Immunotherapy for SepsisOxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis
P2860
Q24558950-C03A90AF-9F11-4B70-B4BA-F60F357B7154Q24654724-B5A7016F-3867-42CF-80FF-68BD0603490DQ24670544-BE4C25A5-C1AD-4F15-9EDB-BB9CF84A0FBEQ24792307-BE623602-E25C-4BE6-863F-F75F4975D3FBQ26830445-36C237F8-A295-4A32-94DF-73AA3316F07BQ26996658-91434475-7525-40CA-B854-5F9A756236DFQ33404640-F9CA5A32-9C90-4643-99FF-7F3492BACF24Q33631108-30A14D6D-98F2-4F57-97C0-9879C750AB8CQ33822465-DC56AC88-FCBE-44AC-9463-187EC2D96506Q34726541-D63B7BE3-EF2F-4C1A-994C-5B1F1104518FQ34771631-05FFC427-092E-4461-B743-35215CFE600BQ35045653-6CB36F7E-498A-4FAA-99F9-2A0E55174D47Q35048770-DBE45C49-A00E-41EE-AB06-6E91D333C111Q35176262-3D908B06-AA66-4E3B-A978-109B3845D1DAQ35219104-966DD310-DB6D-4613-9F2E-7D9011BAB04AQ36176895-22166744-3614-47DB-AB27-68C7D6265195Q36249299-5CDC4259-B5C3-4774-BF71-150639781579Q36310139-B0CDD5DC-72DB-403D-A74A-A7AE943034E8Q36667000-18D8E970-2B76-474D-83E9-1C46A1B343A0Q36880764-185A67B0-417F-4213-9697-9F2A6EB90CD4Q37029217-265883EC-41D3-4CA8-9583-22BEF8192E80Q37233599-F4258361-5FD6-4D35-9A11-47128DD928D8Q37367885-05F5269C-3B0E-4951-9F33-E02C1AB45846Q37392947-F435C052-9083-45D9-883C-C917A28CAC65Q37398233-3A5B7D4A-187C-4B77-BBC4-4F719BF8799BQ37487962-AF4B4576-CE31-4910-8D99-2AFB6203DA18Q37543457-1B96BB52-1F53-4123-80AF-394B6801A88FQ37626123-1E0BD8F4-FA3C-484F-9045-FFB95C793CFBQ37655890-2326CDE1-E4D8-4CD4-91A9-06AFEABAB58AQ38068423-A462E684-065A-45E4-BABD-F7F80F68BEE3Q38084633-C9257100-1B43-4672-B6E5-13A2DB804F22Q38428613-D8DA3185-C140-4DAF-920D-AC270D67C3EEQ38482485-923D752B-EE9A-4C74-80DB-0187E8EC799EQ39099480-6824160D-D484-4B63-8725-AF81D0AEBEECQ40272427-FB966CAB-A8DB-4986-B674-06FD89AB1A51Q41577433-C6AE0AEA-F537-4545-9A2E-F27DFDB4230CQ42963656-CEF1127F-57FF-409D-8DDE-7150F48B5CD4Q43112082-E69FF3C5-5B3E-4168-9637-FF1A2657C2B1Q57160595-F753D260-99CB-4773-8D70-30A377B73799Q58764867-BFE689F6-0A17-42D8-957F-6E2EE600F9E5
P2860
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators
description
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of the American Medical Association
@fr
artículu científicu espublizáu en 2000
@ast
im April 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 5 April 2000)
@en
vedecký článok (publikovaný 2000/04/05)
@sk
vědecký článek publikovaný v roce 2000
@cs
wetenschappelijk artikel (gepubliceerd op 2000/04/05)
@nl
наукова стаття, опублікована у квітні 2000
@uk
name
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@ast
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@en
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@nl
type
label
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@ast
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@en
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@nl
prefLabel
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@ast
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@en
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@nl
P2093
P921
P1476
E5 murine monoclonal antiendot ...... trial. E5 Study Investigators
@en
P2093
D R Graham
H V Dedhia
M C Birmingham
N MacIntyre
P J Scannon
P304
P407
P577
2000-04-05T00:00:00Z